Dr. Lukas Martin
Chief Executive Officer & Co-Founder
translational medicine combining basic and clinical research with data-driven methods and artificial intelligence
Priv.-Doz. Dr. med. Lukas Martin, MHBA
I am Co-Founder and Chief Executive Officer at Clinomic GmbH, a company that creates groundbreaking solutions for the critically ill by combining translational medical research, data science and computational intelligence. With a patient-centric view, Clinomic combine state-of-the-art research with modern technologies to enable an optimal treatment for every patient.
I graduated in Medicine and Health Business Administration and received with honors the Venia legendi in Anesthesiology and Intensive Care Medicine at RWTH Aachen University. I am a consultant and group lead at the Department of Intensive and Intermediate Care at the University Hospital RWTH Aachen and a honorary senior visiting lecturer at Queen Mary University, School of Medicine and Dentistry, London.
My expertise lies in translational medicine combining basic and clinical research with data-driven methods and artificial intelligence. My projects are supported by several funding organizations including the German Research Foundation (DFG), the Federal Ministry of Education and Research (BMBF), and the European Institute for Innovation & Technology (EIT Health), a body of the European Union in the framework of HORIZON 2020. My work was recognized by multiple national and international awards including the Karl-Thomas prize and the Fresenius fellowship of the German Society of Anesthesia and Intensive Care Medicine (DGAI) as well as the inaugural Chaudry award of the American Shock Society. I am an editor of Journal SHOCK, Molecular Medicine, Journal of Cellular and Molecular Medicine (JCMM) and a guest associate editor of Frontiers in Immunology (Inflammation).